PT - JOURNAL ARTICLE AU - Robert Hinch AU - William J M Probert AU - Anel Nurtay AU - Michelle Kendall AU - Chris Wymant AU - Matthew Hall AU - Katrina Lythgoe AU - Ana Bulas Cruz AU - Lele Zhao AU - Andrea Stewart AU - Luca Ferretti AU - Daniel Montero AU - James Warren AU - Nicole Mather AU - Matthew Abueg AU - Neo Wu AU - Anthony Finkelstein AU - David G Bonsall AU - Lucie Abeler-Dörner AU - Christophe Fraser TI - OpenABM-Covid19 - an agent-based model for non-pharmaceutical interventions against COVID-19 including contact tracing AID - 10.1101/2020.09.16.20195925 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.16.20195925 4099 - http://medrxiv.org/content/early/2020/09/22/2020.09.16.20195925.short 4100 - http://medrxiv.org/content/early/2020/09/22/2020.09.16.20195925.full AB - SARS-CoV-2 has spread across the world, causing high mortality and unprecedented restrictions on social and economic activity. Policymakers are assessing how best to navigate through the ongoing epidemic, with models being used to predict the spread of infection and assess the impact of public health measures. Here, we present OpenABM-Covid19: an agent-based simulation of the epidemic including detailed age-stratification and realistic social networks. By default the model is parameterised to UK demographics and calibrated to the UK epidemic, however, it can easily be re-parameterised for other countries. OpenABM-Covid19 can evaluate non-pharmaceutical interventions, including both manual and digital contact tracing. It can simulate a population of 1 million people in seconds per day allowing parameter sweeps and formal statistical model-based inference. The code is open-source and has been developed by teams both inside and outside academia, with an emphasis on formal testing, documentation, modularity and transparency. A key feature of OpenABM-Covid19 is its Python interface, which has allowed scientists and policymakers to simulate dynamic packages of interventions and help compare options to suppress the COVID-19 epidemic.Competing Interest StatementM.A. and N.W. are employees of Alphabet, Inc., a provider of the Exposure Notification System; no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThe study was funded by an award from the Li Ka Shing Foundation to CF. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work does not require approval from a IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing not applicable, no new data generated.